These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

736 related articles for article (PubMed ID: 24628478)

  • 1. A network meta-analysis of the efficacy of belatacept, cyclosporine and tacrolimus for immunosuppression therapy in adult renal transplant recipients.
    Goring SM; Levy AR; Ghement I; Kalsekar A; Eyawo O; L'Italien GJ; Kasiske B
    Curr Med Res Opin; 2014 Aug; 30(8):1473-87. PubMed ID: 24628478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Belatacept for kidney transplant recipients.
    Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
    Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
    Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Belatacept-versus cyclosporine-based immunosuppression in renal transplant recipients with pre-existing diabetes.
    Rostaing L; Neumayer HH; Reyes-Acevedo R; Bresnahan B; Florman S; Vitko S; Heifets M; Xing J; Thomas D; Vincenti F
    Clin J Am Soc Nephrol; 2011 Nov; 6(11):2696-704. PubMed ID: 21921152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Utilization and Clinical Outcomes for Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients.
    Wen X; Casey MJ; Santos AH; Hartzema A; Womer KL
    Am J Transplant; 2016 Nov; 16(11):3202-3211. PubMed ID: 27137884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients.
    Webster A; Woodroffe RC; Taylor RS; Chapman JR; Craig JC
    Cochrane Database Syst Rev; 2005 Oct; (4):CD003961. PubMed ID: 16235347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients.
    Penninga L; Penninga EI; Møller CH; Iversen M; Steinbrüchel DA; Gluud C
    Cochrane Database Syst Rev; 2013 May; (5):CD008817. PubMed ID: 23728681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study).
    Durrbach A; Pestana JM; Pearson T; Vincenti F; Garcia VD; Campistol J; Rial Mdel C; Florman S; Block A; Di Russo G; Xing J; Garg P; Grinyó J
    Am J Transplant; 2010 Mar; 10(3):547-57. PubMed ID: 20415898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.
    Jones-Hughes T; Snowsill T; Haasova M; Coelho H; Crathorne L; Cooper C; Mujica-Mota R; Peters J; Varley-Campbell J; Huxley N; Moore J; Allwood M; Lowe J; Hyde C; Hoyle M; Bond M; Anderson R
    Health Technol Assess; 2016 Aug; 20(62):1-594. PubMed ID: 27578428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2-year results from the long-term extension of a phase II study.
    Grinyo J; Alberu J; Contieri FL; Manfro RC; Mondragon G; Nainan G; Rial Mdel C; Steinberg S; Vincenti F; Dong Y; Thomas D; Kamar N
    Transpl Int; 2012 Oct; 25(10):1059-64. PubMed ID: 22816557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Belatacept Compared With Tacrolimus for Kidney Transplantation: A Propensity Score Matched Cohort Study.
    Cohen JB; Eddinger KC; Forde KA; Abt PL; Sawinski D
    Transplantation; 2017 Oct; 101(10):2582-2589. PubMed ID: 27941427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indirect treatment comparison of belatacept versus tacrolimus from a systematic review of immunosuppressive therapies for kidney transplant patients.
    Muduma G; Hart WM; Patel S; Odeyemi AO
    Curr Med Res Opin; 2016 Jun; 32(6):1065-72. PubMed ID: 26907083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized Controlled Clinical Trial Comparing Belatacept With Tacrolimus After De Novo Kidney Transplantation.
    de Graav GN; Baan CC; Clahsen-van Groningen MC; Kraaijeveld R; Dieterich M; Verschoor W; von der Thusen JH; Roelen DL; Cadogan M; van de Wetering J; van Rosmalen J; Weimar W; Hesselink DA
    Transplantation; 2017 Oct; 101(10):2571-2581. PubMed ID: 28403127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).
    Vincenti F; Charpentier B; Vanrenterghem Y; Rostaing L; Bresnahan B; Darji P; Massari P; Mondragon-Ramirez GA; Agarwal M; Di Russo G; Lin CS; Garg P; Larsen CP
    Am J Transplant; 2010 Mar; 10(3):535-46. PubMed ID: 20415897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys.
    Pestana JO; Grinyo JM; Vanrenterghem Y; Becker T; Campistol JM; Florman S; Garcia VD; Kamar N; Lang P; Manfro RC; Massari P; Rial MD; Schnitzler MA; Vitko S; Duan T; Block A; Harler MB; Durrbach A
    Am J Transplant; 2012 Mar; 12(3):630-9. PubMed ID: 22300431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Belatacept: a novel immunosuppressive agent for kidney transplant recipients.
    Charpentier B
    Expert Rev Clin Immunol; 2012 Nov; 8(8):719-28. PubMed ID: 23167683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Belatacept: a new biologic and its role in kidney transplantation.
    Su VC; Harrison J; Rogers C; Ensom MH
    Ann Pharmacother; 2012 Jan; 46(1):57-67. PubMed ID: 22215686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study.
    Rostaing L; Massari P; Garcia VD; Mancilla-Urrea E; Nainan G; del Carmen Rial M; Steinberg S; Vincenti F; Shi R; Di Russo G; Thomas D; Grinyó J
    Clin J Am Soc Nephrol; 2011 Feb; 6(2):430-9. PubMed ID: 21051752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study.
    Durrbach A; Pestana JM; Florman S; Del Carmen Rial M; Rostaing L; Kuypers D; Matas A; Wekerle T; Polinsky M; Meier-Kriesche HU; Munier S; Grinyó JM
    Am J Transplant; 2016 Nov; 16(11):3192-3201. PubMed ID: 27130868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance immunosuppression for adults undergoing liver transplantation: a network meta-analysis.
    Rodríguez-Perálvarez M; Guerrero-Misas M; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011639. PubMed ID: 28362060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.